Skip to main content

Advertisement

SpringerLink
Log in

Characterisation of disseminated tumor cells in the bone marrow of breast cancer patients by the Thomsen–Friedenreich tumor antigen

  • Original Paper
  • Published:
Histochemistry and Cell Biology Aims and scope Submit manuscript

Abstract

The detection of disseminated tumor cells in the bone marrow (DTC-BM) of breast cancer patients has proved prognostic significance in all stages of the disease. Further characterisation of those cells could help to improve the biological understanding of metastases, develop targeted therapies and define surface markers for enrichment techniques. The Thomsen–Friedenreich (TF) antigen has been shown to be a tumor specific antigen in breast cancer. The aim of this study was to investigate the expression of TF on DTC-BM in 25 patients. Bone marrow samples were first double-stained by a Cy3 conjugated cytokeratin (CK) antibody (ab) A45 B/B3 (IgG) and anti-TF ab Nemod 2 (IgM), followed by Cy2 conjugated goat anti-mouse IgM ab. For further characterisation samples were also double-stained with anti-TF ab Nemod 2 (IgM), followed by Cy2 conjugated goat anti-mouse IgM ab, and anti MUC1 ab A76-A/C7 IgG, followed by Cy3 conjugated goat anti-mouse IgG. CK positive DTC-BM showed co-expression of TF antigen in 22/23 patients (96%) and 61 of 62 detected cells (98%). Mononuclear BM cells without CK expression were also negative for TF. All of the TF positive cells showed strong MUC1 expression. This is the first study showing co-expression of CK and TF as markers of DTC-BM. Double staining experiments of TF and MUC1 expression showed that MUC1 is the carrier protein of TF in these cells. As TF is a specific marker of DTC-BM, it could be used as a target for antibody based therapy and immunomagnetic enrichment techniques for the isolation of DTC-BM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • Baldus SE, Zirbes TK, Hanisch FG, Kunze D, Shafizadeh ST, Nolden S, Monig SP, Schneider PM, Karsten U, Thiele J, Holscher AH, Dienes HP (2000) Thomsen–Friedenreich antigen presents as a prognostic factor in colorectal carcinoma: a clinicopathologic study of 264 patients. Cancer 88:1536–1543

    Article  CAS  PubMed  Google Scholar 

  • Barr N, Taylor CR, Young T, Springer GF (1989) Are pancarcinoma T and Tn differentiation antigens? Cancer 64:834–841

    CAS  PubMed  Google Scholar 

  • Becker N (2001) Development of the incidence and mortality of breast cancer. Radiologie 41:337–343

    Article  CAS  Google Scholar 

  • Braun S, Hepp F, Kentenich CR, Janni W, Pantel K, Riethmuller G, Willgeroth F, Sommer HL (1999) Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin Cancer Res 5:3999–4004

    CAS  PubMed  Google Scholar 

  • Braun S, Kentenich C, Janni W, Hepp F, de Waal J, Willgeroth F, Sommer H, Pantel K (2000a) Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 18:80–86

    CAS  PubMed  Google Scholar 

  • Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmuller G, Schlimok G (2000b) Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342:525–533

    CAS  PubMed  Google Scholar 

  • Braun S, Schlimok G, Heumos I, Schaller G, Riethdorf L, Riethmuller G, Pantel K (2001) ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res 61:1890–1895

    CAS  PubMed  Google Scholar 

  • Braun S, Vogl F, Schlimok G, Diel IJ, Coombes CR, Gerber B, Janni W, Gebauer G, Pantel K (2003) Pooled analysis of prognostic impact of occult metastatic cells (OMC) in bone marrow: 10-year survival of 3448 breast cancer patients. Proc Am Soc Clin Oncol (abstr 3402) 22:847

    Google Scholar 

  • Cao Y, Stosiek P, Springer GF, Karsten U (1996) Thomsen–Friedenreich-related carbohydrate antigens in normal adult human tissues: a systematic and comparative study. Histochem Cell Biol 106:197–207

    Article  CAS  PubMed  Google Scholar 

  • Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N (2002) Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347:567–575

    Article  PubMed  Google Scholar 

  • Gebauer G, Fehm T, Merkle E, Beck EP, Lang N, Jager W (2001) Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol 19:3669–3674

    CAS  PubMed  Google Scholar 

  • Gerber B, Krause A, Muller H, Richter D, Reimer T, Makovitzky J, Herrnring C, Jeschke U, Kundt G, Friese K (2001) Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J Clin Oncol 19:960–971

    CAS  PubMed  Google Scholar 

  • Goletz S, Cao Y, Danielczyk A, Ravn P, Schoeber U, Karsten U (2003) Thomsen–Friedenreich antigen: the “hidden” tumor antigen. Adv Exp Med Biol 535:147–162

    CAS  PubMed  Google Scholar 

  • Hirao T, Sakamoto Y, Kamada M, Hamada S, Aono T (1993) Tn antigen, a marker of potential for metastasis of uterine cervix cancer cells. Cancer 72:154–159

    CAS  PubMed  Google Scholar 

  • Imai J, Ghazizadeh M, Naito Z, Asano G (2001) Immunohistochemical expression of T, Tn and sialyl-Tn antigens and clinical outcome in human breast carcinoma. Anticancer Res 21:1327–1334

    CAS  PubMed  Google Scholar 

  • Janni W, Gastroph S, Hepp F, Kentenich C, Rjosk D, Schindlbeck C, Dimpfl T, Sommer H, Braun S (2000) Prognostic significance of an increased number of micrometastatic tumor cells in the bone marrow of patients with first recurrence of breast carcinoma. Cancer 88:2252–2259

    Article  CAS  PubMed  Google Scholar 

  • Jeschke U, Richter DU, Hammer A, Briese V, Friese K, Karsten U (2002) Expression of the Thomsen–Friedenreich antigen and of its putative carrier protein mucin 1 in the human placenta and in trophoblast cells in vitro. Histochem Cell Biol 117:219–226

    Article  CAS  PubMed  Google Scholar 

  • Karsten U, Butschak G, Cao Y, Goletz S, Hanisch FG (2004) A new monoclonal antibody (A78-G/A7) to the Thomsen–Friedenreich pan-tumor antigen. Hybridoma 14:37–44

    Google Scholar 

  • Kasper M, Stosiek P, Typlt H, Karsten U (1987) Histological evaluation of three new monoclonal anti-cytokeratin antibodies. 1. Normal tissues. Eur J Cancer Clin Oncol 23:137–147

    Article  CAS  PubMed  Google Scholar 

  • Khaldoyanidi SK, Glinsky VV, Sikora L, Glinskii AB, Mossine VV, Quinn TP, Glinsky GV, Sriramarao P (2003) MDA-MB-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by Thomsen–Friedenreich antigen-galectin-3 interactions. J Biol Chem 278:4127–4134

    Article  CAS  PubMed  Google Scholar 

  • Klemi PJ, Parvinen I, Pylkkanen L, Kauhava L, Immonen-Raiha P, Rasanen O, Helenius H (2003) Significant improvement in breast cancer survival through population-based mammography screening. Breast 12:308–313

    Article  PubMed  Google Scholar 

  • Landys K, Persson S, Kovarik J, Hultborn R, Holmberg E (1998) Prognostic value of bone marrow biopsy in operable breast cancer patients at the time of initial diagnosis: results of a 20-year median follow-up. Breast Cancer Res Treat 49:27–33

    Article  CAS  PubMed  Google Scholar 

  • Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U, Coombes RC (1999) Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet 354:197–202

    Article  CAS  PubMed  Google Scholar 

  • Naume B, Borgen E, Beiske K, Herstad TK, Ravnas G, Renolen A, Trachsel S, Thrane-Steen K, Funderud S, Kvalheim G (1997) Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood. J Hematother 6:103–114

    CAS  PubMed  Google Scholar 

  • Pantel K, Braun S (2001) Molecular determinants of occult metastatic tumor cells in bone marrow. Clin Breast Cancer 2:222–228

    CAS  PubMed  Google Scholar 

  • Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, Funke I, Izbicki JR, Riethmuller G (1993) Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85:1419–1424

    CAS  PubMed  Google Scholar 

  • Pantel K, Muller V, Auer M, Nusser N, Harbeck N, Braun S (2003) Detection and clinical implications of early systemic tumor cell dissemination in breast cancer. Clin Cancer Res 9:6326–6334

    CAS  PubMed  Google Scholar 

  • Price MR, Rye PD, Petrakou E, Murray A, Brady K, Imai S, Haga S, Kiyozuka Y, Schol D, Meulenbroek MF, Snijdewint FG, von Mensdorff-Pouilly S, Verstraeten RA, Kenemans P, Blockzjil A, Nilsson K, Nilsson O, Reddish M, Suresh MR, Koganty RR, Fortier S, Baronic L, Berg A, Longenecker MB, Hilgers J (1998) Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif. 1998. Tumour Biol 19 (Suppl 1):1–20

    Article  Google Scholar 

  • van Rooijen JJ, Jeschke U, Kamerling JP, Vliegenthart JF (1998) Expression of N-linked sialyl Le(x) determinants and O-glycans in the carbohydrate moiety of human amniotic fluid transferrin during pregnancy. Glycobiology 8:1053–1064

    Article  PubMed  Google Scholar 

  • Schindlbeck C, Janni W, Schaffer P, Shabani N, Schmitt M, Harbeck N, Sommer H, Braun S (2002) Tumor biology of primary breast cancer and minimal residual disease. Acta Med Austriaca 29(Suppl 59):27–31

    Google Scholar 

  • Schindlbeck C, Janni W, Shabani N, Rack B, Gerber B, Schmitt M, Harbeck N, Sommer H, Braun S, Friese K (2004) Comparative analysis between the HER2 status in primary breast cancer tissue and the detection of isolated tumor cells in the bone marrow. Breast Cancer Res Treat 87:65–74

    CAS  PubMed  Google Scholar 

  • Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, Kaufmann M, Diebold J, Arnholdt H, Muller P, Bischoff J, Harich D, Schlimok G, Riethmuller G, Eils R, Klein CA (2003) From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA 100:7737–7742

    Article  CAS  PubMed  Google Scholar 

  • Sloane JP, Ormerod MG, Neville AM (1980) Potential pathological application of immunocytochemical methods to the detection of micrometastases. Cancer Res 40:3079–3082

    CAS  PubMed  Google Scholar 

  • Springer GF, Desai PR, Scanlon EF (1976) Blood group MN precursors as human breast carcinoma-associated antigens and “naturally” occurring human cytotoxins against them. Cancer 37:169–176

    CAS  PubMed  Google Scholar 

  • Springer GF, Desai PR, Murthy MS (1978) Histochemical methods for the demonstration of Thomsen–Friedenreich antigen in cell suspensions and tissue sections. Klin Wochenschr 56:761–765

    Article  PubMed  Google Scholar 

  • Takanami I (1999) Expression of Thomsen–Friedenreich antigen as a marker of poor prognosis in pulmonary adenocarcinoma. Oncol Rep 6:341–344

    CAS  PubMed  Google Scholar 

  • Wiedswang G, Borgen E, Karesen R, Kvalheim G, Nesland JM, Qvist H, Schlichting E, Sauer T, Janbu J, Harbitz T, Naume B (2003) Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 21:3469–3478

    Article  CAS  PubMed  Google Scholar 

  • Wolf MF, Ludwig A, Fritz P, Schumacher K (1988) Increased expression of Thomsen–Friedenreich antigens during tumor progression in breast cancer patients. Tumour Biol 9:190–194

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Mrs. S. Kunze for excellent technical assistance.

Author information

Authors and Affiliations

  1. First Department of Obstetrics and Gynecology, Ludwig Maximilians University of Munich, Maistrasse 11, 80337, Munich, Germany

    Christian Schindlbeck, Udo Jeschke, Sandra Schulze, Wolfgang Janni, Brigitte Rack, Harald Sommer & Klaus Friese

  2. Max-Delbrück-Center for Molecular Medicine Berlin-Buch, R. Rössle Str. 10, 13125, Berlin-Buch, Germany

    Uwe Karsten

Authors
  1. Christian Schindlbeck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Udo Jeschke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sandra Schulze
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Uwe Karsten
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wolfgang Janni
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Brigitte Rack
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Harald Sommer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Klaus Friese
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Schindlbeck.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schindlbeck, C., Jeschke, U., Schulze, S. et al. Characterisation of disseminated tumor cells in the bone marrow of breast cancer patients by the Thomsen–Friedenreich tumor antigen. Histochem Cell Biol 123, 631–637 (2005). https://doi.org/10.1007/s00418-005-0781-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00418-005-0781-6

Keywords

Search

Navigation